Last updated: 2026-09-06 15:00:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Fulgent Genetics, Inc. (FLGT) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $19,73, with a market capitalization of $551,41M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13,46 to $31,04. This page covers its latest market performance, valuation, price trends and company information.
$551,41M | |
$19,64 | |
$189,89 | |
$2,73 | |
$19,65 | |
194,56K | |
-- | |
-- | |
$31,04 | |
$13,46 | |
-- | |
-- |
Fulgent Genetics, Inc. (FLGT) last closed at $19,65 as of 2026-09-04 23:31:00, unchanged from the previous close of $19,65.
During the latest regular trading session, FLGT traded between $2,73 and $189,89, with a volume of 194,56K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Fulgent Genetics, Inc. (FLGT) moved from $19,42 to $19,73, representing a gain of 1,57% ($0,30).
The stock traded between $19,37 and $19,85 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 288,43 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 35,6%
FLGT is currently trading at $19,73, placing it 35,6% of the way from its 52-week low of $13,46 to its 52-week high of $31,04. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 1315 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Fulgent Genetics, Inc. (FLGT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.